

Title (en)
CYTOKINE ENHANCED IMMUNOTHERAPY FOR BRAIN TUMORS

Title (de)
ZYTOKIN-ERHOEHTE IMMUNTHERAPIE GEGEN GEHIRNTUMORE

Title (fr)
IMMUNOTHERAPIE AMELIOREE PAR CYTOKINE POUR TUMEURS CEREBRALES

Publication
EP 0930892 A1 19990728 (EN)

Application
EP 97910921 A 19971015

Priority

- US 9718455 W 19971015
- US 73159796 A 19961016

Abstract (en)
[origin: WO9816246A1] A therapy for treatment of patients with cancer utilizing the combination of a cytokine in a pharmaceutically acceptable carrier for systemic administration and a cytokine in a pharmaceutically acceptable carrier for local administration is described. In the most preferred embodiment, brain tumors are treated with a cytokine such as GM-CSF administered systemically, most preferably in combination with tumor antigen such as replication incompetent tumor cells, and a cytokine such as IL-2 or IL-4 administered locally, most preferably in a vehicle providing release over a period of time, such as transduced cells, again most preferably replication incompetent tumor cells, or incorporated into microparticulate vehicles such as polymeric microspheres.

IPC 1-7
A61K 39/00

IPC 8 full level
A61K 9/50 (2006.01); **A61K 9/00** (2006.01); **A61K 35/12** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 47/30** (2006.01); **A61P 35/00** (2006.01); **A61K 48/00** (2006.01)

CPC (source: EP US)
A61K 9/0085 (2013.01 - EP); **A61K 39/0011** (2013.01 - EP US); **A61P 35/00** (2018.01 - EP); **A61K 48/00** (2013.01 - EP)

Cited by
WO2020252405A1; WO2020252404A1; WO2021050789A1; WO2021040736A1; WO2019241315A1; WO2020123716A1; WO2020185632A1

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9816246 A1 19980423; AU 4818297 A 19980511; CA 2267977 A1 19980423; EP 0930892 A1 19990728; JP 2001502331 A 20010220

DOCDB simple family (application)
US 9718455 W 19971015; AU 4818297 A 19971015; CA 2267977 A 19971015; EP 97910921 A 19971015; JP 51850498 A 19971015